成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

ZM323881 hydrochloride

  Cat. No.:  DC1083  
Chemical Structure
193000-39-4
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
Tel:+86-021-58447131
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
ZM323881 a receptor tyrosine kinase inhibitor of VEGFR-2 (Flk-1), PDGFR-beta, EGFR, and FGFR1
Cas No.: 193000-39-4
Chemical Name: 5-((7-Benzyloxyquinazolin-4-yl)amino)-4-fluoro-2-methylphenol hydrochloride
Synonyms: ZM323881; ZM 323881; ZM-323881; ZM323881 HCl; ZM323881 hydrochloride
SMILES: CC1=C(O)C=C(NC2=C3C=CC(OCC4=CC=CC=C4)=CC3=NC=N2)C(F)=C1.Cl
Formula: C22H19ClFN3O2
M.Wt: 411.115
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Description: ZM 323881 hydrochloride is a potent and selective inhibitor of human vascular endothelial growth factor receptor 2 (VEGFR-2/KDR) activity. ZM 323881 hydrochloride inhibits VEGF-A-induced endothelial cell proliferation in vitro (IC50 = 8 nM). Selectively inhibits VEGFR-2 (IC50 = 2 nM) over VEGFR-1 and a range of other receptor tyrosine kinases. For the detailed information about the solubility of ZM 323881 hydrochloride in water, the solubility of ZM 323881 hydrochloride in DMSO, the solubility of ZM 323881 hydrochloride in PBS buffer, the animal experiment（test） of ZM 323881 hydrochloride,the in vivo,in vitro and clinical trial test of ZM 323881 hydrochloride,the cell experiment（test） of ZM 323881 hydrochloride,the IC50, EC50 and Affinity of ZM 323881 hydrochloride, please contact DC Chemicals.
MSDS
COA
LOT NO. DOWNLOAD
2018-0101
Cat. No. Product name Field of application
DC47302 AZD8601 AZD8601 is an mRNA designed to produce vascular endothelial growth factor A (VEGF-A). AZD8601 accelerates diabetic wound healing.
DC47279 Pegaptanib sodium Pegaptanib sodium is an RNA aptamer directed against vascular endothelial growth factor (VEGF)-165. Pegaptanib could be used for the study of neovascular age-related macular degeneration (AMD) .
DC46934 (Rac)-SAR131675 (Rac)-SAR131675 is the racemate of SAR131675. SAR131675 is a potent and selective VEGFR3 inhibitor with an IC50 of 23 nM.
DC46933 Timtraxanib Timtraxanib (AVI-3207) is a selective VEGF-2 inhibitor. Timtraxanib can be used for the research of senile macular degeneration.
DC46437 VEGFR-3-IN-1 VEGFR-3-IN-1 is a potent and selective VEGFR3 inhibitor with an IC50 of 110.4 nM. VEGFR-3-IN-1 significantly inhibits proliferation and migration of VEGF-C-induced human dermal lymphatic endothelial cells (HDLEC), MDA-MB-231, and MDA-MB-436 cells by inactivating the VEGFR3 signaling pathway, and also effectively inhibits breast cancer growth.
DC46175 TIE-2/VEGFR-2 kinase-IN-2 TIE-2/VEGFR-2 kinase-IN-2 is a potent dual VEGFR2 and Tie-2 inhibitor with pIC50 values of 8.61 and 8.56, respectively. TIE-2/VEGFR-2 kinase-IN-2 is an anti-angiogenic agent and can be used for cancer research.
DC46126 Axitinib-d3 Axitinib-d3 (AG-013736-d3) is deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively.
DC45294 5α-Hydroxycostic acid 5α-Hydroxycostic acid, a eudesmane-type sesquiterpene, is isolated from the herb Laggera alata. 5α-Hydroxycostic acid inhibits angiogenesis and suppresses breast cancer cell migration through regulating VEGF/VEGFR2 and Ang2/Tie2 pathways.
DC42427 SU5204 SU5204, a tyrosine kinase extracted from patent US5792783A, has IC50s of 4 and 51.5 μM for FLK-1 (VEGFR-2) and HER2, respectively.
DC42426 (Z)-Orantinib (Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive of Flk‐1/KDR, PDGFRβ, and FGFR1, with IC50s of 2.1, 0.008, and 1.2 μM, respectively. (Z)-Orantinib is a potent antiangiogenic and antitumor agent that induces regression of established tumors.
X